Session Title: Vascular Diseases III
Session Date/Time: Sunday 29/09/2013 | 08:00-10:00
Paper Time: 09:36
Venue: Hall 3 (Level 0)
First Author: A.Souka EGYPT
Co Author(s): S. Soliman
To evaluate the efficacy of a single intravitreal bevacizumab injection in controlling disease progression in eyes with stage III retinopathy of prematurity (ROP) and in facilitating subsequent pars plana vitrectomy in cases of stage IV ROP.
Faculty of Medicine, Alexandria Main University Hospital (fundus photography and follow up) i-Care eye Hospital (intravitreal injection)
A retrospective review of the records of premature infants that had ROP and received a single intravitreal bevacizumab injection (0.625 mg/0.25 ml) was performed. Eyes that completed 6 months of post injection follow up were included. The need for additional treatments (laser, cryotherapy, re-injection or surgery) to control disease progression for stage III ROP was evaluated. The surgical steps and outcome in eyes with stage IV ROP after injection were evaluated.
Records of 41 eyes of 21 premature infants (11 of them are females) with ROP (35 eyes with stage III and 6 eyes with stage IV b) were reviewed. 100% of eyes injected for stage III ROP needed no additional treatment and 80% of eyes (28/35) showed evidence of peripheral retinal vascularization at 6 months of follow up. The surgeon observed easiness of fibrovascular tissue dissection with less bleeding in 100% of preoperatively injected stage IV b eyes in comparison to his previous surgical experience in similar non injected cases. The extent of preoperative retinal detachment and fibrovascular proliferation inversely correlated with the final postoperative anatomical outcome.
A single intravitreal bevacizumab injection is sufficient in controlling disease progression in eyes with stage III ROP without the need of additional treatments. Preoperative intravitreal bevacizumab facilitated surgical intervention with less bleeding and easier dissection in eyes with stage IV b ROP. The extent of preoperative retinal detachment is the main determining factor in the final anatomical outcome in stage IV b ROP.